Structure via PubChem · Public domain (PubChem)
censavudine
Sign in to saveAlso known as festinavir
Censavudine (INN; development code BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023.
Chemical data
- Formula
- C12H12N2O4
- Molecular weight
- 248.23 g/mol
- IUPAC name
- 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- HIV-1 infection
via ChEMBL · EBI
~1 min read
Encyclopedic overview
2 sectionsContents
- Renaming
- References
Censavudine (INN; development code BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023.
==Renaming== Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir, etc.).
Excerpted from Wikipedia’s “censavudine” article, available under the CC BY-SA 4.0 licence.